Several of them have been investigated in DLBCL cell lines and models: Nx-2127, a BTK degrader, blocks the proliferation of ibrutinib-resistant DLBCL cells in vitro [258]; Nx-5948 selectively breaks down BTK, which was confirmed by proteomics in DLBCL cells [259]; and KT-413 is a protein degrader that hits IL1 receptor-associated kinase 4 and displays preference towards MYD88-mutant DLBCL models [260]. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.